What is the share price of Lasa Supergenerics Ltd (LASA) today?
The share price of LASA as on 15th July 2025 is ₹12.15. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Lasa Supergenerics Ltd (LASA) share?
The past returns of Lasa Supergenerics Ltd (LASA) share are- Past 1 week: -2.25%
- Past 1 month: -3.26%
- Past 3 months: -30.97%
- Past 6 months: -53.32%
- Past 1 year: -49.79%
- Past 3 years: -61.18%
- Past 5 years: -72.10%
What are the peers or stocks similar to Lasa Supergenerics Ltd (LASA)?
The peers or stocks similar to Lasa Supergenerics Ltd (LASA) include:What is the market cap of Lasa Supergenerics Ltd (LASA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lasa Supergenerics Ltd (LASA) is ₹62.13 Cr as of 15th July 2025.What is the 52 week high and low of Lasa Supergenerics Ltd (LASA) share?
The 52-week high of Lasa Supergenerics Ltd (LASA) is ₹33.49 and the 52-week low is ₹8.42.What is the PE and PB ratio of Lasa Supergenerics Ltd (LASA) stock?
The P/E (price-to-earnings) ratio of Lasa Supergenerics Ltd (LASA) is -4.21. The P/B (price-to-book) ratio is 0.64.Which sector does Lasa Supergenerics Ltd (LASA) belong to?
Lasa Supergenerics Ltd (LASA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Lasa Supergenerics Ltd (LASA) shares?
You can directly buy Lasa Supergenerics Ltd (LASA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Lasa Supergenerics Ltd
LASA Share Price
12.152.02% (-0.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
LASA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LASA Performance & Key Metrics
LASA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -4.21 | 0.64 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.43 | 6.45 | 0.81% |
LASA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
LASA Company Profile
Lasa Supergenerics Limited is engaged in the manufacturing of anthelmintics/veterinary active pharmaceutical ingredient (API). The Company also manufactures bulk drugs
SUNPHARMA
PE Ratio
36.94
36.94
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.73
22.73
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
60.29
60.29
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
55.89
55.89
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.40
18.40
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
LASA Forecast
LASA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
LASA
LASA
Income
Balance Sheet
Cash Flow
Annual Normal View
LASA Income Statement
LASA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 200.92 | 246.94 | 170.04 | 167.49 | 202.44 | 137.40 | 131.37 | 104.44 | 147.46 | 155.70 | ||||||||||
Raw Materials | 141.67 | 172.06 | 126.21 | 87.01 | 102.11 | 94.46 | 110.12 | 79.28 | 151.85 | 160.10 | ||||||||||
| Power & Fuel Cost | 6.03 | 6.64 | 6.71 | 7.92 | 8.06 | 7.06 | 7.72 | 7.45 | ||||||||||||
| Employee Cost | 9.55 | 10.27 | 11.74 | 13.42 | 14.01 | 7.15 | 6.35 | 5.37 | ||||||||||||
| Selling & Administrative Expenses | 2.24 | 4.45 | 4.65 | 6.54 | 9.72 | 9.03 | 6.98 | 5.64 | ||||||||||||
| Operating & Other expenses | 19.93 | 8.78 | 9.15 | 22.41 | 21.16 | 11.26 | 24.85 | 13.15 | ||||||||||||
EBITDA | 21.50 | 44.74 | 11.58 | 30.19 | 47.38 | 8.44 | -24.65 | -6.45 | -4.39 | -4.40 | ||||||||||
| Depreciation/Amortization | 7.69 | 18.17 | 19.31 | 17.34 | 15.82 | 14.51 | 13.42 | 10.67 | 12.30 | 12.30 | ||||||||||
| PBIT | 13.81 | 26.57 | -7.73 | 12.85 | 31.56 | -6.07 | -38.07 | -17.12 | -16.69 | -16.70 | ||||||||||
| Interest & Other Items | 11.68 | 11.35 | 8.38 | 8.12 | 2.06 | 0.06 | 4.19 | 1.99 | 2.69 | 2.69 | ||||||||||
| PBT | 2.13 | 15.22 | -16.11 | 4.73 | 29.50 | -6.13 | -42.26 | -19.11 | -19.38 | -19.39 | ||||||||||
| Taxes & Other Items | -0.22 | 2.89 | -4.07 | 1.11 | 6.72 | -0.81 | -3.65 | 2.62 | -4.63 | -4.62 | ||||||||||
| Net Income | 2.35 | 12.33 | -12.04 | 3.62 | 22.78 | -5.32 | -38.61 | -21.73 | -14.75 | -14.77 | ||||||||||
| EPS | 470.00 | 10.76 | -5.27 | 1.14 | 5.60 | -1.17 | -7.71 | -4.34 | -2.95 | -2.95 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | — | 0.00 | 0.00 | 0.00 | 0.00 |
LASA Company Updates
LASA Stock Peers
LASA Past Performance & Peer Comparison
LASA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lasa Supergenerics Ltd | -4.21 | 0.64 | — |
| Sun Pharmaceutical Industries Ltd | 36.94 | 5.57 | 0.95% |
| Cipla Ltd | 22.73 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 60.29 | 15.18 | 0.94% |
LASA Stock Price Comparison
Compare LASA with any stock or ETFCompare LASA with any stock or ETF
LASA
LASA Holdings
LASA Shareholdings
LASA Promoter Holdings Trend
LASA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
LASA Institutional Holdings Trend
LASA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
LASA Shareholding Pattern
LASA Shareholding Pattern
LASA Shareholding History
LASA Shareholding History
Foreign Institutions
smallcases containing LASA stock
smallcases containing LASA stock
Looks like this stock is not in any smallcase yet.
LASA Events
LASA Events
LASA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
LASA Dividend Trend
No dividend trend available
LASA Upcoming Dividends
LASA Upcoming Dividends
No upcoming dividends are available
LASA Past Dividends
LASA Past Dividends
Cash Dividend
Ex DateEx DateSep 16, 2022
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Sep 16, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
LASA Stock News & Opinions
LASA Stock News & Opinions
Articles & Videos
Earnings
Lasa Supergenerics reports standalone net loss of Rs 14.29 crore in the March 2025 quarter
Net Loss of Lasa Supergenerics reported to Rs 14.29 crore in the quarter ended March 2025 as against net loss of Rs 15.30 crore during the previous quarter ended March 2024. Sales rose 71.52% to Rs 39.14 crore in the quarter ended March 2025 as against Rs 22.82 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 14.76 crore in the year ended March 2025 as against net loss of Rs 21.73 crore during the previous year ended March 2024. Sales rose 36.52% to Rs 142.45 crore in the year ended March 2025 as against Rs 104.34 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales39.1422.82 72 142.45104.34 37 OPM %8.71-17.48 -4.392.07 - PBDT5.69-4.54 LP 8.580.33 2500 PBT1.79-7.20 LP -3.72-10.34 64 NP-14.29-15.30 7 -14.76-21.73 32 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Lasa Supergenerics to table results
Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Lasa Supergenerics to discuss results
Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Lasa Supergenerics to hold EGM
Lasa Supergenerics announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 22 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Lasa Supergenerics to hold board meeting
Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Lasa Supergenerics cancels board meeting
Lasa Supergenerics has cancelled the board meeting which was scheduled to be held on 24 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Lasa Supergenerics to conduct board meeting
Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Lasa Supergenerics reports standalone net loss of Rs 3.23 crore in the September 2024 quarter
Net Loss of Lasa Supergenerics reported to Rs 3.23 crore in the quarter ended September 2024 as against net loss of Rs 0.02 crore during the previous quarter ended September 2023. Sales rose 62.10% to Rs 39.39 crore in the quarter ended September 2024 as against Rs 24.30 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales39.3924.30 62 OPM %2.014.32 - PBDT1.500.57 163 PBT-1.31-2.11 38 NP-3.23-0.02 -16050 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Lasa Supergenerics to conduct board meeting
Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Lasa Supergenerics AGM scheduled
Lasa Supergenerics announced that the 9th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -2.52%, vs industry avg of 10.15%
Over the last 5 years, market share decreased from 0.07% to 0.04%